Cardiac adverse events associated with quetiapine: Disproportionality analysis of FDA adverse event reporting system
Open Access
- 10 April 2023
- journal article
- research article
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 29 (9) , 2705-2716
Abstract
Objective: Quetiapine, an atypical second‐generation antipsychotic drug, is approved for treatment of schizophrenia, bipolar disorder, and depression. Due to the limitations of clinical trials, the association between quetiapine and rare cardiac adverse events (AEs) is still unclear. This study is to evaluate quetiapine‐associated cardiac AEs through data mining of FDA Adverse Event Reporting System (FAERS).Methods: Reporting odds ratio (ROR) was used to quantify the signals of quetiapine‐related cardiac AEs from the first quarter (Q1) of 2018–2022 Q1. Serious and nonserious cases were compared, and signals were prioritized using a rating scale.Results: A total of 1004 cases of quetiapine‐associated cardiac AEs were identified, with 31 signals being detected, among which 13 AEs were identified as new and unexpected signals. Besides, nine and 22 cardiac AEs were identified as moderate and weak clinical priority. The median TTO for moderate and weak clinical priority signals were 0 and 4 days, respectively. All of the cardiac AEs had early failure type characteristics, suggesting that most of the patients developed cardiac AEs in a few days after quetiapine treatment, and that the risk of cardiac AEs occurrence would be gradually decreased over time.Conclusion: Our study provided valuable evidence for health‐care professionals to mitigate the risk of quetiapine‐associated cardiac AEs based on an extensive analysis of a real‐world, large‐sample FAERS database, and prioritize cardiac AE signals.Keywords
Funding Information
- National Natural Science Foundation of China (82104476)
This publication has 43 references indexed in Scilit:
- A case series of patients with lamotrigine toxicity at one center from 2003 to 2012Clinical Toxicology, 2013
- Illustration of the Weibull Shape Parameter Signal Detection Tool Using Electronic Healthcare Record DataDrug Safety, 2013
- Antipsychotics and Torsadogenic Risk: Signals Emerging from the US FDA Adverse Event Reporting System DatabaseDrug Safety, 2013
- Adverse Effects of Second-Generation Antipsychotics in Children and AdolescentsJournal of Clinical Psychopharmacology, 2012
- Cardiovascular risk assessment of atypical antipsychotic drugs in a zebrafish modelJournal of Applied Toxicology, 2011
- Metabolic and cardiovascular adverse effects associated with antipsychotic drugsNature Reviews Endocrinology, 2011
- Comparative safety of antipsychotics in the WHO pharmacovigilance database: the haloperidol caseInternational Journal of Clinical Pharmacy, 2011
- Atypical Antipsychotic Drugs and the Risk of Sudden Cardiac DeathNew England Journal of Medicine, 2009
- Second-Generation AntipsychoticsDrug Safety, 2006
- A Randomized Evaluation of the Effects of Six Antipsychotic Agents on QTc, In the Absence and Presence of Metabolic InhibitionJournal of Clinical Psychopharmacology, 2004